期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
丙酸氟替卡松吸入气雾剂联合ACEI/ARB治疗IgA肾病的临床观察 被引量:2
1
作者 袁湘宁 杨敬华 +6 位作者 唐家乐 廖中华 罗丽颖 肖湘成 许辉 周巧玲 李晓照 《中国现代医学杂志》 CAS 2020年第18期57-61,共5页
目的探讨丙酸氟替卡松吸入气雾剂联合血管紧张素转化酶抑制剂或血管紧张素受体阻断剂(ACEI/ARB)治疗IgA肾病的有效性和安全性。方法采用前瞻性随机对照研究方法,将经3个月足量ACEI/ARB治疗,尿蛋白仍>0.5g/d的原发性IgA肾病患者随机... 目的探讨丙酸氟替卡松吸入气雾剂联合血管紧张素转化酶抑制剂或血管紧张素受体阻断剂(ACEI/ARB)治疗IgA肾病的有效性和安全性。方法采用前瞻性随机对照研究方法,将经3个月足量ACEI/ARB治疗,尿蛋白仍>0.5g/d的原发性IgA肾病患者随机分为治疗组和对照组,每组17例。治疗组给予丙酸氟替卡松吸入气雾剂250μg/次,2次/d,同时联合ACEI/ARB治疗;对照组仅给予ACEI/ARB治疗。入组后第3、6和9月各随访1次。结果治疗组与对照组0、3、6和9个月的的尿总蛋白/尿肌酐比值在不同组间有差别(P<0.05),在不同时间、变化趋势上无差别(P>0.05)。治疗组与对照组0、3、6和9个月的的eGFR在不同时间、不同组间、变化趋势上无差别(P<0.05)。治疗组与对照组0、3、6和9个月的尿总蛋白/尿肌酐比值变化率、eGFR变化率在不同时间、不同组间、下降趋势上有差别(P<0.05)。所有患者未发生严重不良反应。结论丙酸氟替卡松吸入气雾剂联合ACEI/ARB治疗IgA肾病可有效降低患者的蛋白尿水平,延缓eGFR下降。 展开更多
关键词 IgA肾病/肾小球肾炎IgA 丙酸氟替卡松/糖皮质激素类 血管紧张素转换酶抑制药 血管紧张素受体阻断剂 蛋白尿
下载PDF
腕部桡动脉-头静脉内瘘通畅的影响因素研究 被引量:9
2
作者 刘倩倩 唐旸烁 +6 位作者 伍婷 蒲佳曦 陈金彪 肖湘成 周巧玲 肖平 钟永 《中国现代医学杂志》 CAS 2019年第16期64-68,共5页
目的分析影响终末期肾脏疾病(ESRD)维持性血液透析患者自体动静脉瘘(AVF)通畅性的因素。方法选取2016年12月-2018年1月于中南大学湘雅医院肾内科行腕部桡动脉-头静脉标准内瘘手术ESRD患者195例。分析其人口统计学资料、临床资料、生化... 目的分析影响终末期肾脏疾病(ESRD)维持性血液透析患者自体动静脉瘘(AVF)通畅性的因素。方法选取2016年12月-2018年1月于中南大学湘雅医院肾内科行腕部桡动脉-头静脉标准内瘘手术ESRD患者195例。分析其人口统计学资料、临床资料、生化指标及术后应用抗凝治疗是否与AVF通畅相关。结果195例患者随访1年,8例患者失访,4例患者死亡,行肾移植手术者12例,29例患者出现术后并发症。AVF的1年生存率为91.6%。多因素Cox比例风险模型分析中,抗凝史[H^R=3.412(95%CI:1.225,9.503),P=0.019]是AVF通畅的影响因素。结论术后应用抗凝治疗会降低AVF的1年通畅率。 展开更多
关键词 动静脉瘘 肾透析 肾病
下载PDF
Involvement of hydrogen sulfide in the progression of renal fibrosis 被引量:4
3
作者 Yu Wang Qi-Qi Xing +11 位作者 Jing-Ke Tu Wen-Bin Tang Xiang-Ning Yuan Yan-Yun Xie Wei Wang Zhang-Zhe Peng Ling Huang Hui Xu Jiao Qin xiang-cheng xiao Li-Jian Tao Qiong-Jing Yuan 《Chinese Medical Journal》 SCIE CAS CSCD 2019年第23期2872-2880,共9页
Objective:Renal fibrosis is the most common manifestation of chronic kidney disease(CKD).Noting that existing treatments of renal fibrosis only slow disease progression but do not cure it,there is an urgent need to id... Objective:Renal fibrosis is the most common manifestation of chronic kidney disease(CKD).Noting that existing treatments of renal fibrosis only slow disease progression but do not cure it,there is an urgent need to identify novel therapies.Hydrogen sulfide(H2S)is a newly discovered endogenous small gas signaling molecule exerting a wide range of biologic actions in our body.This review illustrates recent experimental findings on the mechanisms underlying the therapeutic effects of H2S against renal fibrosis and highlights its potential in future clinical application.Data sources:Literature was collected from PubMed until February 2019,using the search terms including"Hydrogen sulfide,""Chronic kidney disease"MRenal interstitial fibrosis,"Kidney disease,""Inflammation factor,""Oxidative stress,""Epithelialto-mesenchymal transition,""H2S donor,""Hypertensive kidney dysfunction,""Myofibroblasts,""Vascular remodeling,""transforming growth factor(TGF)-beta/Smads signaling,"and"Sulfate potassium channels."Study selection:Literature was mainly derived from English articles or articles that could be obtained with English abstracts.Article type was not limited.References were also identified from the bibliographies of identified articles and the authors5 files.Results:The experimental data confirmed that H2S is widely involved in various renal pathologies by suppressing inflammation and oxidative stress,inhibiting the activation of fibrosis-related cells and their cytokine expression,ameliorating vascular remodeling and high blood pressure,stimulating tubular cell regeneration,as well as reducing apoptosis,autophagy,and hypertrophy.Therefore,H2S represents an alternative or additional therapeutic approach for renal fibrosis.Conclusions:We postulate that H2S may delay the occurrence and progress of renal fibrosis,thus protecting renal function.Further experiments are required to explore the precise role of H2S in renal fibrosis and its application in clinical treatment. 展开更多
关键词 Hydrogen sulfide Renal interstitial fibrosis Chronic kidney disease
原文传递
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection 被引量:1
4
作者 Wei Lin Jue Fan +14 位作者 Long-Fei Hu Yan Zhang Joshua DOoi Ting Meng Peng Jin Xiang Ding Long-Kai Peng Lei Song Rong Tang Zhou xiao Xiang Ao xiang-cheng xiao Qiao-Ling Zhou Ping xiao Yong Zhong 《Chinese Medical Journal》 SCIE CAS CSCD 2021年第8期935-943,共9页
Background::Since 2019,a novel coronavirus named 2019 novel coronavirus(2019-nCoV)has emerged worldwide.Apart from fever and respiratory complications,acute kidney injury has been observed in a few patients with coron... Background::Since 2019,a novel coronavirus named 2019 novel coronavirus(2019-nCoV)has emerged worldwide.Apart from fever and respiratory complications,acute kidney injury has been observed in a few patients with coronavirus disease 2019.Furthermore,according to recent findings,the virus has been detected in urine.Angiotensin-converting enzyme II(ACE2)has been proposed to serve as the receptor for the entry of 2019-nCoV,which is the same as that for the severe acute respiratory syndrome.This study aimed to investigate the possible cause of kidney damage and the potential route of 2019-nCoV infection in the urinary system.Methods::We used both published kidney and bladder cell atlas data and new independent kidney single-cell RNA sequencing data generated in-house to evaluate ACE2 gene expression in all cell types in healthy kidneys and bladders.The Pearson correlation coefficients between ACE2 and all other genes were first generated.Then,genes with r values larger than 0.1 and P values smaller than 0.01 were deemed significant co-expression genes with ACE2.Results::Our results showed the enriched expression of ACE2 in all subtypes of proximal tubule(PT)cells of the kidney.ACE2 expression was found in 5.12%,5.80%,and 14.38%of the proximal convoluted tubule cells,PT cells,and proximal straight tubule cells,respectively,in three published kidney cell atlas datasets.In addition,ACE2 expression was also confirmed in 12.05%,6.80%,and 10.20%of cells of the proximal convoluted tubule,PT,and proximal straight tubule,respectively,in our own two healthy kidney samples.For the analysis of public data from three bladder samples,ACE2 expression was low but detectable in bladder epithelial cells.Only 0.25%and 1.28%of intermediate cells and umbrella cells,respectively,had ACE2 expression.Conclusion::This study has provided bioinformatics evidence of the potential route of 2019-nCoV infection in the urinary system. 展开更多
关键词 2019-nCoV Acute kidney injury Angiotensin-converting enzyme 2 BLADDER COVID-19 KIDNEY RNA sequence analysis Single-cell analysis
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部